

CytoSorb®

Benefits of independent use



- Setup and treat - whenever your patient requires CytoSorb®
- Be independent from concomitant renal replacement therapy (RRT)
- Benefit from RRT hemoperfusion mode or Purifi platform

▼ The Challenge

A chance to protect organ function and enhance outcomes



- Critically ill patients **often suffer from an accumulation of cytokines** during **systemic hyperinflammation**.
- **The aim of early removal of excessive levels of cytokines by CytoSorb® is to achieve hemodynamic stability, shock reversal and to provide outcome benefits.** Standalone CytoSorb® **enables this early start**, independent from RRT.



- During **rhabdomyolysis, myoglobin from damaged muscular tissue** gets released into the blood stream.
- Standalone use of CytoSorb® **can eliminate myoglobin early**, which could accumulate in the kidneys and **lead to acute kidney injury (AKI)**.



- In liver dysfunction **autointoxication** (accumulated liver toxins) as well as **hyperinflammation** may be present.
- The use of CytoSorb® as a standalone treatment **enables early liver support** by **removing elevated levels of bilirubin** and **attenuating hyperinflammation** by cytokine removal.

Prevent antithrombotic (AT) induced excessive bleeding



- The widespread use of **antithrombotic drugs*** can pose a **serious and significant risk of bleeding** especially in cardiovascular surgery patients.
- **AT removal during CPB surgery** by CytoSorb® **helps to reduce bleeding risks.**⁽¹⁾

Only CytoSorb® hemoadsorption therapy is expressly approved to remove excessive levels of cytokines, bilirubin and myoglobin from whole blood and to help reach subtherapeutic levels of the antithrombotic drugs* during CPB.

* Ticagrelor and Rivaroxaban

02

▼ The Solution

Overcome challenges by using CytoSorb® in standalone configurations



Start wherever needed in the ER, OR, ICU or IMC **

- Prior to onset of kidney failure⁽²⁾ and
- Independent from RRT or other platforms⁽³⁾.



Use CytoSorb® in standalone configuration, the easiest form of adsorptive blood purification.



Use CytoSorb® intraoperatively, independent from CPB.

(e.g. MiECC*** during CPB surgery, when there is no possibility of CytoSorb® integration)

03

▼ The Benefits

Early intervention is key. Timing and dosing matter!



Early intervention with CytoSorb® can help to save lives

".... for each additional hour in CytoSorb® therapy delay, the odds of mortality... increased by 1.5%..."⁽⁴⁾



Standalone application may allow higher blood flows compared to CytoSorb® RRT integration, increasing the treatment dose.



CytoSorb® Standalone Therapy

whenever and wherever needed

CytoSorb®, an approved and powerful tool for standalone settings



** Emergency Room, Operating Room, Intensive Care Unit or Intermediate Care

*** Minimally invasive Extracorporeal Circulation (MiECC)

Act now to best support your patient!

Use CytoSorb® on PuriFi, the tailored standalone platform




- **Quick and easy setup** combined with **automatic CytoSorb® priming**, done within a few minutes.
- **Maintenance free pressure monitoring** and **autolevelling bubble catcher** simplifies use.
- **Easy to learn** and use wherever needed, in the ER, OR, ICU, IMC **.

PuriFi
by CytoSorbents

** Emergency Room, Operating Room, Intensive Care Unit or Intermediate Care

Use CytoSorb® on your RRT device in hemoperfusion mode

- Standalone hemoperfusion mode might already be available on your RRT device.
- Setup and application is simpler compared to typical RRT applications.



Visit
www.cyto.zone/setup

and get to know more about the CytoSorb® integration options

References:

1. Hassan et al., Ann Thorac Surg 2019; 108(1):45-51
2. Zarbock et al., Nat Rev Nephrol 2023; 19:401-417
3. Napp et al., Blood Purif 2019; 48(3):203-214
4. Kogelmann et al., J Clin Med 2021; 10(13):2939

CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany

T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

follow us on     | www.cytosorb.com

The clinical and preclinical data and results obtained with the CytoSorb® adsorber are not transferable to other products. CytoSorb® should only be administered by personnel who have been properly trained in administration of extracorporeal therapies. CytoSorb® is not available for commercial sale in USA. CytoSorb® and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2023, CytoSorbents Europe GmbH. All rights reserved. B1342R01ENG2023